

Product datasheet for TL311769V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

LDHA Human shRNA Lentiviral Particle (Locus ID 3939)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: LDHA Human shRNA Lentiviral Particle (Locus ID 3939)

Locus ID: 3939

Synonyms: GSD11; HEL-S-133P; LDHM; PIG19

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: LDHA - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 001135239, NM 001165414, NM 001165415, NM 001165416, NM 005566, NR 028500,

NM 005566.1, NM 005566.2, NM 005566.3, NM 001135239.1, NM 001165416.1,

NM 001165415.1, NM 001165414.1, BC067223, BC067223.1, BM995301, NM 001165415.2,

NM 005566.4

UniProt ID: P00338

Summary: The protein encoded by this gene catalyzes the conversion of L-lactate and NAD to pyruvate

and NADH in the final step of anaerobic glycolysis. The protein is found predominantly in muscle tissue and belongs to the lactate dehydrogenase family. Mutations in this gene have been linked to exertional myoglobinuria. Multiple transcript variants encoding different isoforms have been found for this gene. The human genome contains several non-

transcribed pseudogenes of this gene. [provided by RefSeq, Sep 2008]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our custom shRNA service.





Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).